# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
GSK presented interim results from the DREAMM-8 phase 3 trial at ASCO 2024. Blenrep (belantamab mafodotin) with PomDex showed a...
GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (rani...
https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-delaware-state-court-daubert-ruling/
DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement in primary endpoint of progre...
Goldman Sachs analyst Rajan Sharma initiates coverage on GSK (NYSE:GSK) with a Neutral rating and announces Price Target of ...